Yes, Illumina completed the acquisition of SomaLogic's specific assets—including SomaScan Assay Services, Authorized Sites, and KREX technology—from Standard BioTools for an upfront cash payment of 350 million dollars, alongside potential near-term earnout considerations. This strategic transaction was designed to expand Illumina's footprint into the rapidly growing proteomics and multi-omics market, allowing the company to combine its world-leading next-generation gene sequencing platforms with advanced protein analysis capabilities to serve biomedical researchers globally.